Two-deoxyglucose as an Anti-metabolite in Human Carcinoma Cell Line RPMI-2650 and Drug-resistant Variants

Anticancer Research

Volumn 24, Issue 2 A, 2004, Pages 433-440

  Keenan, J ^a   Liang, Y ^a   Clynes, M ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

2 DG uptake; Altered glucose metabolism; Drug resistance

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIMETABOLITE; DEOXYGLUCOSE; GLUCOSE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE TRANSPORTER; GLUTAMINE; HEXOKINASE; IODOACETIC ACID; MELPHALAN; PACLITAXEL DERIVATIVE; PENTOSE PHOSPHATE;

CANCER RESISTANCE; CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ACCUMULATION; DRUG MECHANISM; DRUG SELECTIVITY; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; NOSE CARCINOMA; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS;

ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DEOXYGLUCOSE; DRUG RESISTANCE, NEOPLASM; GLUCOSE; HUMANS; NASAL SEPTUM; NOSE NEOPLASMS; TRITIUM;

EID: 2442509090     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Hamilton E, Fennel M and Stafford D: Modification of tumour glucose metabolism for therapeutic benefit. Acta Oncologica 34: 429-433, 1995.
2. Floridi A, Bruno T, Miccadei S, Fanciulli M, Federico A and Paggi MG: Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. Biochem Pharm 56: 841-849, 1998.
3. Choi Jw, Yoon DJ, Lee Hw, Han Dp and Ahn Yh: Antisense GLUT1 RNA suppresses the transformating phenotypes of NIH 3T3 cells transformed by N-Ras. Yonsei Med J 36: 480-486, 1995.
4. Chun JK, Lee YL, Kim C, Choi SR, Kim M, Lee K, Jeong JM, Lee DS, Jang JJ and Lee MC: Mechanisms related to F-18-fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. J Nuc Med 40: 339-346, 1999.
5. Waki A, Kato H, Yano R, Sadato N, Yokoyama A, Ishii Y, Yonekura Y and Fujibashi Y: The importance of glucose transport activity as the rate limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nuc Med Biol 25: 593-597, 1998.
6. Aloj L, Caraco C, Jagoda E, Eckelman WC and Neumann RD: Glut-1 and hexokinase expression: Relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 59: 4709-4714, 1999.
7. Mohanti B, Rath GK, Anantha N, Kannan V, Das BS, Chandramouli BAR, Banerjee AK, Das S, Jena A, Ravichandran R, Sahi UP, Kumar R, Kapoor N, Kalia V, Dwarakanath BS and Jain V: Improving cancer radiotherapy with 2-deoxy-d-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiation Oncology Biol Phys 35: 103-111, 1996.
8. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B and Bergh J: PET studies in patients with locally advanced and/or metastatic breast cancer - a method for early therapy evaluation. J Clin Oncology 13: 1470-1477, 1995.
9. Yasuda S, Kubota M, Tajima T, Tajima T, Umemura S, Fujii H, Takahashi W, Ide M. and Shohtsu A: A small breast cancer detected by PET. Japn J Clin Oncol 29: 387-389, 1999.
10. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW and Miraldi F: Positron emisson tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: A surgicopathologic study. J Clin Oncology 17: 41-45, 1999.
11. Bell SE, Quinn DM, Kellett GL and Warr JR: 2-deoxy-D-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis. B J Cancer 78(11): 1464-1470, 1998.
12. Haga N, Naito M, Seimiya H, Tomida A, Dong J and Tsuruo T: 2-Deoxyglucose inhibits chemotherapeutic drug-induced apoptosis in human monocytic leukaemia U937 cells with inhibition of c-Jun N-terminal kinase 1 stress-activated protein kinase activation. Int J Cancer 76 (1): 86-90, 1998.
13. Berlangieri SU, Scott AM, Knight SR, Fitt GJ, Hennessy OF, Tochon-Danguy HJ, Clarke CP and McKay WJ: F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothoracic Sur 16: S25-S30, 1999.
14. Laemmli E and Favre M: Mutation of the head of bacteriophage T4. J Mol Biol 80: 575-579, 1973.
15. Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedures and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979.
16. Bergmeyer HU, Grassel M and Walter HE: In: Methods of Enzymatic Analysis (Bergmeyer HU ed) 3rd ed, Volume II, 222-223, Verlag Chemie, Deerfield Beach FL, 1983.
17. Lee Cy: Glucose-6-phosphate dehydrogenase from mouse. Methods Enzymol 89: 252-257, 1982.
18. Martin A and Clynes M: Acid phosphatase endpoint for in vitro toxicity testing. In Vitro Dev Biol 27A: 183-184, 1991.
19. Stokkel MP, Draisma A and Pauwels EK: Positron emission tomography with 2-18F-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: Therapy response monitoring in colorectal and lung tumors, head and neck cancer, hepatocellular carcinoma and sarcoma. J Cancer Res Clin Oncol 127: 278-285, 2001.
20. Bently J, Bell SE, Quinn DM, Kellett GL and Warr JR: 2-deoxy-D-glucose toxicity and transport in human multidrug-resistant KB carcinoma cell lines. Oncology Res 8(2): 77-84, 1996.
21. Kalia VK: Optimizing radiation therapy of brain tumours by combination of 5-bromo-2-deoxy-uridine and 2-deoxy-D-glucose. Indian J Med Res 109: 182-187, 1999.
22. Pauwels EKJ, Sturm EJC, Bombardieri E, Cleton FJ and Stokkel MPM: Positron-emission tomography with F-18 fluorodeoxyglucose Part 1. Biochemical uptake mechanisms and its implications for clinical studies. J Can Res Clin Oncol 126(10): 549-559, 2000.
23. Maublant J, Vuillez JP, Talbot JN, Lumbroso J, Muratet JP, Herry JY and Artus JC: Positron emission tomography (PET) and f-18-fluorodeoxyglucose (FDG) in cancerology. Bulletin du Cancer 85 (11): 935-950, 1998.
24. Lyon R, Cohen JS, Faustino PJ, Megnin F and Myers CE: Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. Cancer Res 48: 870-877, 1988.
25. Faniculli M, Bruno T, Castiglione S, Del Carlo C, Paggi M and Floridi A: Glucose metabolism in adriamycin-sensitive and - resistant LoVo human colon carcinoma cells. Oncology Res 5: 357-362, 1993.
26. Miccadi S, Fanciulli M, Bruno T, Paggi MG and Floridi A: Energy metabolism of adriamycin-sensitive and -resistant Ehrlich ascites tumor cells. Oncology Res 8: 27-35, 1996.
27. Liang Y, Meleady P, Cleary I, McDonnell S, Connolly L and Clynes M: Selection with mephalan or taxol yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. E J Cancer 37: 1041-1052, 2001.
28. Kaplan O, Jaroszewski JW, Clarke R, Fairchild CR, Schoenlein P, Goldenberg S, Gottesman MM and Cohen JS: The multidrug resistance phenotype P-31 nuclear-magnetic resonance characterisation and 2-deoxyglucose toxicity. Cancer Res 51 (6): 1638-1644, 1991.
29. Lorke DE, Kruger M, Buchert R, Bohuslavizki KH, Clausen M and Schumacher U: In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line. J Nuc Med 42(4): 646-654, 2001.
30. Mueckler M: Facilitative glucose transporters. Eur J Biochem 219: 713-725, 1994.
31. Dang CV and Semenza GL: Oncogenic alterations of metabolism. TIBS 24: 68-72, 1999.
32. Younes M, Lechago LV, Somoano JR, Mosharaf M and Lechago J: Wide expression of the human erythrocyte glucose transporter Glut 1 in human cancers. Cancer Res 56: 1164-1167, 1996.
33. Noguchi Y, Marat D, Saito A, Yoshikawa T, Doi C, Fukuzawa K, Tsuburaya A, Satoh S and Ito T: Expression of facilitative glucose transporters in gastric tumors. Hepato-gastroenterology 26: 2683-2689, 1999.
34. Reisser C, Eichtlorn K and Herold-Mende C: Glucose uptake in malignant tumors of the head and neck. HNO 47: 712-717, 1999.
35. Sebastian S and Kenkare UW: Expression of two type II-like tumor hexokinasee RNA transcripts in cancer cell lines. Tumor Biology 19: 253-260, 1998.
36. Arora K and Pedersen: Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J Biol Chem 263: 17422-17428, 1988.
37. Minn H, Kangas L, Knuutila V, Paul R and Sipila H: Determination of 2-Fluoro-2-deoxyglucose uptake and ATP level for evaluating drug effects in neoplastic-cells. Res Exp Med 191: 27-35, 1991.
38. Ahmed N, Williams JF and Weidemann MJ: Glycolytic, glutaminolytic and pentose-phosphate pathways in promyelocytic HL60 and DMSO-differentiated HL60 cells. Biochem Mol Biol Intl 1055-1067, 1993.
39. Smith TAD, Titley JC and McCready VR: Proliferation is associated with 2-deoxy-D-[1-H-3]glucose uptake by T47D breast tumour and SW 480 and SW620 colonic tumour cells. Nuc Med and Biol 25(5): 481-485, 1993.